Pharmaceutical Executive: April 2025

View the Pharmaceutical Executive April 2025 issue in an interactive format.

The job of pharma-driven messaging and reputation management may never be more important than it is today.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and stretching the boundaries in healthcare exploration.

Four tips for midsized companies when entering new global markets.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Introducing a new series highlighting ways pharma companies can up their game in winning earned media—and ultimately deliver greater impact and value from their messaging.

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer advertising amid policy and government agency overhauls in the US.

The formula for future-proofing pharmaceutical networks to withstand any disruption.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.